biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > No posts for over a month

<< Previous

Bullboard Posts

Next >>

Comment by TheTruth1234on Nov 10, 2023 11:32am

93 Views

Post# 35728511

RE:RE:RE:RE:RE:RE:RE:No posts for over a month

Boomskid wrote:
xB3 doesn't need to work for somebody to make a pump and dump out of it. It’s a great promote. It can be promoted against the $3 billion Denali, run up with a big pump, and then dumped before the sad news of xB3's failure needs to be made public.

But every Bioasis CEO has made unequivocal statements that there are no known or perceived problems with xB3. For 12 years I have reported to this forum that I have asked Bioasis CEOs in every way imaginable way whether there are any real or perceived problems with xB3. I asked this because Bioasis never got any good deals done and explanations are necessary.

I reported on this forum Rob Hutchison's response to my question about why Bioasis wasn't taking xB3 into preclinical studies. He answered with a rhetorical question, essentially asking, "Why would Bioasis take on that risk when pharmas can pay us and take that risk themselves." Of course, there were never any deals of any real value done.

I put Bioasis CEOs on the record on purpose so that they could never deny saying and touting it. If it is ever shown that they, indeed, did know of problems, then we have it documented that they deceived shareholders and other investors. Documented!!!

So, what should happen? Regulators ought to ask Bioasis's pharmaceutical and institutional partners, including WuXi Biologics and Chiesi, whether any of them reported to Bioasis any problems with xB3. Should be done.

And I continuously reported this stuff for the entire 12 years that talked about Bioasis on this and other forums.

TT, you're so far behind that you think you're in the lead.